Form 8-K - Current report:
SEC Accession No. 0001213900-24-084337
Filing Date
2024-10-02
Accepted
2024-10-02 09:16:42
Documents
20
Period of Report
2024-09-26
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0216216-8k_cero.htm   iXBRL 8-K 48561
2 CONSULTING AGREEMENT, DATED SEPTEMBER 30, 2024, BY AND BETWEEN THE COMPANY AND K ea021621602ex10-1_cero.htm EX-10.1 37967
3 CONSULTING AGREEMENT, DATED SEPTEMBER 30, 2024, BY AND BETWEEN THE COMPANY AND C ea021621602ex10-2_cero.htm EX-10.2 35160
4 CONSULTING AGREEMENT, DATED SEPTEMBER 30, 2024, BY AND BETWEEN THE COMPANY AND A ea021621602ex10-3_cero.htm EX-10.3 36570
5 CONSULTING AGREEMENT, DATED SEPTEMBER 30, 2024, BY AND BETWEEN THE COMPANY AND B ea021621602ex10-4_cero.htm EX-10.4 32774
6 CONSULTING AGREEMENT, DATED SEPTEMBER 30, 2024, BY AND BETWEEN THE COMPANY AND C ea021621602ex10-5_cero.htm EX-10.5 40938
7 PRESS RELEASE, DATED OCTOBER 2, 2024 ea021621602ex99-1_cero.htm EX-99.1 10736
  Complete submission text file 0001213900-24-084337.txt   525678

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE cero-20240926.xsd EX-101.SCH 3798
9 XBRL DEFINITION FILE cero-20240926_def.xml EX-101.DEF 26673
10 XBRL LABEL FILE cero-20240926_lab.xml EX-101.LAB 36817
11 XBRL PRESENTATION FILE cero-20240926_pre.xml EX-101.PRE 25297
22 EXTRACTED XBRL INSTANCE DOCUMENT ea0216216-8k_cero_htm.xml XML 5942
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 241345459
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)